Oxford Biomedica PLC RNS notice of results OXB (8118X)
August 15 2018 - 1:00AM
UK Regulatory
TIDMOXB
RNS Number : 8118X
Oxford Biomedica PLC
15 August 2018
Notice of Interim Results
London, UK - 15 August 2018: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE:OXB), a leading gene and cell
therapy group, will be announcing its interim results for the six
months ended 30 June 2018 on 13 September 2018.
A briefing for analysts will be held at 12:00pm GMT on 13
September 2018 at 85 Gresham Street, London, EC2R 7HE. There will
be a simultaneous live conference call with Q&A and the
presentation will be available on the Group's website at
www.oxfordbiomedica.co.uk. An audio replay file will be made
available shortly afterwards.
Please contact Consilium Strategic Communications for further
details.
- Ends -
For further information, please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive Officer 783 000
Stuart Paynter, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0)20
Mary-Jane Elliott/Matthew Neal/ 3709 5700
Olivia Manser/Laura Thornton
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Bioverativ, Sanofi, Axovant,
Orchard Therapeutics, GC LabCell and Immune Design, through which
it has long-term economic interests in other potential gene and
cell therapy products. Oxford BioMedica is based across several
locations in Oxfordshire, UK and employs more than 320 people.
Further information is available at www.oxfordbiomedica.co.uk.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORDZLFFVVFBBBD
(END) Dow Jones Newswires
August 15, 2018 02:00 ET (06:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024